The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jul 27, 2026
· 2 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Deadline nears to file claim in class-action lawsuit over drug Rexulti
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
-0.297 · LEFT
Ensemble
-0.148 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.055
8,320 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Deadline nears to file claim in class-action lawsuit over drug Rexulti
MONTREAL
THE CANADIAN PRESS
PUBLISHED 2 HOURS AGO
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.
Canadians have until Aug. 27 to file a claim for their share of a $4.75-million settlement over the antipsychotic medication used to treat schizophrenia and depression.
Quebec Superior Court approved t…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jul 27, 2026
📰
🔒 Unlock — Starter+
2 outlets covered this story
Side-by-side comparison · bias by outlet · framing analysis